FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Company ProfileNutriband Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NTRB
Nutriband Inc. Stock AnalysisComprehensive stock analysis for Nutriband Inc. (NTRB) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNTRB
NTRB
Nutriband Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
NTRB
Home🔹Stocks🔹Nutriband Inc.

Nutriband Inc.

🇺🇸NTRB•NASDAQ

Nutriband Inc.

🇺🇸NTRB•NASDAQ
Market cap
$77.92M
Sentiment

Your view on NTRB

Mkt Cap
$77.92M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Nutriband Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Gareth Sheridan
Headquarters
121 South Orange Avenue, Orlando, FL, US
Industry
Biotechnology
Sector
Healthcare
CEO
Gareth Sheridan
Headquarters
121 South Orange Avenue, Orlando, FL, US
Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.

The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices.

The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Nutriband Inc., and the rating behind it. NTRB last traded at $6.41; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Nutriband Inc.. Starting points for Nutriband Inc.: EPS -$0.57, beta 1.93 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Nutriband Inc.. Nutriband Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Nutriband Inc.. Trailing twelve-month EPS for Nutriband Inc. stands at -$0.57. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Nutriband Inc.. Nutriband Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Nutriband Inc. valued side by side against its closest peers. Nutriband Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Nutriband Inc., and how their positions are changing. At a $77.9M market value, institutional positions materially move Nutriband Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Nutriband Inc. executives and directors. Shares of Nutriband Inc. have traded between $3.72 and $11.78 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Nutriband Inc.. Nutriband Inc. is a $77.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Nutriband Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Nutriband Inc.. Coverage tracks Nutriband Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

Peer companies

  • ACETAdicet Bio, Inc.
  • ACRVAcrivon Therapeutics, Inc. Common Stock
  • ADAGAdagene Inc.
  • CRVOCervoMed Inc.
  • FBIOFortress Biotech, Inc.
  • GANXGain Therapeutics, Inc.
  • LITSLite Strategy, Inc.
  • RLMDRelmada Therapeutics, Inc.

More Biotechnology companies

  • PTIXProtagenic Therapeutics, Inc.
  • PTNPalatin Technologies, Inc.
  • PTX.AXPrescient Therapeutics Limited
  • PULMPulmatrix, Inc.
  • PVCTProvectus Biopharmaceuticals, Inc.
  • PVLAPalvella Therapeutics, Inc.
  • PXMDPaxMedica, Inc. Common Stock
  • PXXLFPoxel S.A.
  • PYC.AXPYC Therapeutics Limited
  • PYPDPolyPid Ltd.
  • PYXSPyxis Oncology, Inc.
  • PZRXQPhaseRx, Inc.

ETFs holding Nutriband Inc.

Largest holders, then the funds most concentrated in NTRB · % = share of the fund

  • VTIVanguard Total Stock Market ETF0.00%
  • VXFVanguard Extended Market ETF0.00%
  • IWCiShares Micro-Cap ETF
  • VUN.TOVanguard U.S. Total Market Index ETF0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio0.00%
  • VGRO.TOVanguard Growth ETF Portfolio0.00%
  • VBAL.TOVanguard Balanced ETF Portfolio0.00%
NTRB Analysis
Weak
Past1
Growth1
Health5
Profit1
Value1

News

Latest Market News

No comments yet

Be the first to ask a question or say what you make of Nutriband Inc.